bioAffinity
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Select Page

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

by Dale Harrison | Jan 24, 2023 | Press Releases

Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity SAN ANTONIO, TX – Jan 24, 2023 – – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage...

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

by Dale Harrison | Jan 4, 2023 | Press Releases

SAN ANTONIO, TX – Jan 4, 2023 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for...

bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench

by Dale Harrison | Dec 15, 2022 | Press Releases

SAN ANTONIO, TX – Dec. 15, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that...

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

by Dale Harrison | Dec 1, 2022 | Press Releases

bioAffinity reports on a potential therapeutic approach that kills cancer cells without harm to normal cells SAN ANTONIO, TX – Dec. 1, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of...

bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update

by Dale Harrison | Nov 14, 2022 | Press Releases

SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its...

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board

by Dale Harrison | Nov 10, 2022 | Press Releases

SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at the South Texas Veterans Health Care Systems’ Audie L. Murphy...
« Older Entries

Categories

  • Articles (15)
  • Events (34)
  • News (40)
  • Press Releases (56)
  • Publications (15)

Recent Posts

  • bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research January 24, 2023
  • Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning January 23, 2023
  • bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments January 4, 2023
  • Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes December 28, 2022
  • bioAffinity President & CEO to meet with institutional investors and bankers during J.P. Morgan Annual Healthcare Conference in San Francisco, January 9-12, 2023 December 28, 2022

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Copyright © 2023 bioAffinity Technologies, Inc.